Ms Caroline Boulliat | Immunology Franchise Head of Biosimilars for Europe, Middle East and Africa
Hospira

Ms Caroline Boulliat, Immunology Franchise Head of Biosimilars for Europe, Middle East and Africa, Hospira

Responsible for Launching INFLECTRA, (first 'Mab' biosimilar ) in the EMEA region
Potential Value: 2 Billions.
In charge of commercial / Marketing / Market Access activities

back to speakers